Kenji Ishihara, Asuka Ichinomiya, Mami Inami, Tomomi Hashimoto, Rie Yuzawa, Miari Ishizu, Toshie Hirohara, Yoshimi Yashiro, Toshiyuki Takizawa
REGENERATIVE THERAPY 5 96-106 2016年12月 査読有り
We studied the recognition of, interest in, and understanding of induced pluripotent stem (iPS) cells and regenerative medicine in a total of 2659 junior high school, senior high school, and university students. The number of valid responses received was 2396 (90.1%). We report the following seven observations [1]. More than 80% of students reported recognition of iPS cells, regenerative medicine, and Professor Shinya Yamanaka, and a similar number were interested in and supportive of regenerative medicine [2]. Regenerative medicine was viewed as a medical treatment option. However, females were more cautious regarding use of regenerative medicine as a treatment compared with males [3]. Approximately 90% of students were interested in the latest medical care. Among the new treatment methods, they more frequently selected those that they were more familiar with and perceived less invasive to be ideal [4]. Regarding organ or tissue donation in regenerative medicine, students focused more on the characteristics of the donors [5]. Approximately 90% were supportive of storing their own cells. However, approximately 50% of students supported storing iPS cells for use in regenerative medicine [6]. Most students were anxious regarding the side effects, safety, and treatment costs of regenerative medicine, but supported the need of education regarding regenerative medicine [7]. More than 70% of students thought that education of regenerative medicine was necessary for the public. These findings suggest the importance of social approach, in addition to medical approach such as research and development, to improve QOL in community by developing the public understanding of regenerative medicine through science communication and school education, for the establishment of systems to promote this field. (C) 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.